← Back to Search

Behavioral Intervention

Mindful Attention Training for Pediatric Cancer Survivors

N/A

Recruiting

Led By Joaquin Anguera, PhD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Normal or corrected-normal vision and hearing

Age 7-17 at the time of enrollment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 8 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial will test a new training to help with thinking and behavior in kids who have survived cancer.

Who is the study for?

This trial is for children aged 7-17 who have survived pediatric cancer, can follow the study's procedures, and have a guardian to consent. They should speak English fluently, not be on certain cancer treatments that affect participation, and must have had radiation therapy to the brain or neck.

What is being tested?

The study tests an adaptive attention training program against standard questionnaires to see if it improves thinking skills and behavior in kids who've beaten cancer. It's a pilot study which means it's preliminary research before larger studies.

What are the potential side effects?

Since this trial involves attention training exercises and questionnaires rather than medication, traditional side effects are not expected. However, participants may experience fatigue or frustration related to cognitive tasks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My vision and hearing are normal, or corrected to normal.

Select...

I am between 7 and 17 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of participants who complete study

Secondary study objectives

Change in mean performance on a Continuous Performance Task (CPT) over time

Other study objectives

Change in mean performance on a Delay Discounting Task over time

Change in mean performance on a computerized Math Fluency Test

Change in mean performance on a computerized Reading Fluency Test

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: No Contact Group (Not Randomized)Experimental Treatment1 Intervention

An additional thirty participants will be enrolled separately (not randomized) into the no-contact group. Participants in the no-contact group will not complete any study activities for 6-8 weeks after completing the baseline assessments. After this period, participants will be prompted to log into Nexus to complete end of study assessments (same set of assessments administered/completed at baseline).

Group II: Adaptive Attention TrainingExperimental Treatment2 Interventions

Participants will complete approximately 15 hours of an at-home training on a novel adaptive attention training program ('Engage'), which will consist of completing thirty, 30-minute sessions over a total of 6-8 weeks.

Group III: Low-dose Adaptive Attention TrainingActive Control2 Interventions

Participants will complete approximately 1 hour of at-home training on 'Engage' which consists of two, 30-minute sessions at the beginning and middle of a 6-8 week period.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Questionnaires

2013

Completed Phase 2

~4280

Adaptive Attention Training

2019

N/A

~60